InMed Pharmaceuticals Inc.

NasdaqCM:INM

Sector

🏥 Health Care

Industries

💊 Pharmaceuticals

🔬 Clinical Trials

Location

Canada

Market Cap

USD 3.01 M

Share Price

USD 2.49

Avg Daily Volume

1,309,407

Change (1 day)

-0.80%

Change (1 year)

-47.69%

Change (YTD)

-47.47%

InMed Pharmaceuticals Inc. Share Price on June 20, 2025: USD 2.49

InMed Pharmaceuticals Inc. Share Price is USD 2.49 on June 20, 2025, a -47.69% change year over year. Share price reflects current trading price of a company's stock; influenced by market dynamics and company performance.

InMed Pharmaceuticals Inc. 52-week low Share Price is USD 8.62 on June 20, 2025, which is 246.18% above the current Share Price.
InMed Pharmaceuticals Inc. 52-week low Share Price is USD 1.86 on June 20, 2025, which is -25.30% below the current Share Price.
InMed Pharmaceuticals Inc. average Share Price for the last 52 weeks is USD 4.07.

Daily

From:

To:

Zoom:

Key data

Date	Share Price	Share Price	Price to Earnings Ratio (P/E)	Price to Book Ratio (P/B)

NasdaqCM: INM

InMed Pharmaceuticals Inc.

CEO	Mr. Eric A. Adams B.S. Chem., M.I.B.
IPO Date	May 5, 2014
Location	Canada
Headquarters	815 West Hastings Street
Employees	13
Sector	🏥 Health Care
Industries Pharmaceuticals 🔬 Clinical Trials

Description

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.